SCHEMBL24651214

SCHEMBL24651214

CCCC(=O)c1cc(OCC)c(OCC)cc1OCC

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.65
▸ CYP3A4 P08684 1/20 0.65
▸ HSD17B10 Q99714 2/20 0.50
▸ HMGCR P04035 1/20 0.49
▸ TDP1 Q9NUW8 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ TNFRSF1A P19438 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trepibutone SCHEMBL25039 0.86 TSHR (0.61) TSHRCYP3A4HSD17B10ALDH1A1HPGD
Trepibutone SCHEMBL29441541 0.86 TSHR (0.61) TSHRCYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL11684821 0.81 TSHR (0.65) TSHRCYP3A4HSD17B10TDP1ALDH1A1
SCHEMBL27997509 0.79 HMGCR (0.57) TSHRCYP3A4HSD17B10HMGCRTDP1
SCHEMBL10498013 0.79 TSHR (1.00) TSHRCYP3A4HSD17B10TDP1KDM4E
SCHEMBL11683269 0.78 TSHR (0.51) TSHRCYP3A4HSD17B10HMGCRALDH1A1
SCHEMBL24651298 0.78 TSHR (0.51) TSHRCYP3A4HSD17B10HMGCRTDP1
SCHEMBL7012914 0.77 TSHR (0.59) TSHRHSD17B10ALDH1A1HPGDNPC1
SCHEMBL28779453 0.76 HCRTR1 (0.58) TSHRHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL9004517 0.76 THRB (0.48) CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022250569-A1 NOVEL COMPOUND FOR TREATING BILIARY TRACT DISORDERS ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" 2022-12-01 — — WO disclosed
Send feedback